Thursday May 25th 2017

Posts Tagged ‘Paolo Zamboni’

The silent treatment: How Canada has failed MS sufferers

The silent treatment: How Canada has failed MS sufferers

On June 3, 2010, Peter Liu, a scientific director of the Canadian Institutes of Health Research (CIHR) in Ottawa, sent an internal email outlining his thoughts on a procedure causing medical and political schisms—and inciting patient activism. Liu, head of the Institute [Read More]

Paolo Zamboni – a Q&A

Paolo Zamboni – a Q&A

What’s your reaction to the death of Mahir Mostic ? There are thousands of procedures done all over the world. I cannot control what happens in any way. My academic activities cannot control what happens in the world. Do you [Read More]

Inventor of ‘liberation’ treatment blasts skeptics in Alberta government

Inventor of ‘liberation’ treatment blasts skeptics in Alberta government

The Italian researcher behind the controversial ‘liberation’ treatment for multiple sclerosis patients has written a letter to Alberta’s provincial health board, calling its position statement on the treatment “extremely confusing” and [Read More]

 Page 1 of 10  1  2  3  4  5 » ...  Last » 

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]